Perspectives in the Management of Non-Small Cell Lung Cancer

Sequencing Therapies in NSCLC
November 13, 2017 – 
Benjamin P. Levy, MD, reviews sequencing therapies in non–small cell lung cancer and shares his outlook on the future of treatments.
Anti-Angiogenesis in NSCLC
November 13, 2017 – 
Benjamin P. Levy, MD, describes the rationale for targeting angiogenesis therapy in lung cancer, including the method of action for bevacizumab and ramucirumab and utilizing anti-angiogenesis to boost treatment efficacy.
Nondriver NSCLC: Immunotherapy and PD-L1 Expression
November 06, 2017 – 
Benjamin P. Levy, MD, explains the role of immunotherapy in patients with advanced nondriver non–small cell lung cancer and what is known about PD-L1 expression.
Immunotherapy and Chemotherapy in Second-Line NSCLC
November 06, 2017 – 
Benjamin P. Levy, MD, discusses patient and tumor responses to chemotherapy-based options and immunotherapy in the second-line setting and what treatments to use following an immunotherapy/chemotherapy combination in non–small cell lung cancer.
NSCLC: Initiating Second-Line Therapy
October 30, 2017 – 
Benjamin P. Levy, MD, reviews the options for second-line therapy in non–small cell lung cancer including the goals of therapy, factors to consider when deciding on treatment, importance of aggressiveness of disease, and toxicity profiles.
Maintenance Following Chemotherapy in NSCLC
October 30, 2017 – 
Benjamin P. Levy, MD, describes his maintenance strategy following chemotherapy in patients with non–small cell lung cancer.
Nondriver NSCLC: Frontline Systemic Therapy
October 24, 2017 – 
Benjamin P. Levy, MD, explains the factors to consider when deciding on a treatment approach in the frontline setting of advanced nondriver non–small cell lung cancer and the use of immunotherapy/chemotherapy combinations.
Mutation Testing in Nonsquamous NSCLC
October 24, 2017 – 
Benjamin P. Levy, MD, discusses the mutations that are tested in nonsquamous non–small cell lung cancer and the role of PD-L1 testing.
Incentivizing Quality Care in NSCLC
August 02, 2017 – 
Bhuvana Sagar, MD, offers her perspective on the potential use of quality-based incentives in lung cancer.
Considering Real-World Outcomes in NSCLC
August 02, 2017 – 
Bhuvana Sagar, MD, reviews second-line treatment options in non—small cell lung cancer and treatment cost versus value.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.